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Abstract
Background: Non-invasive tests have been constructed and evaluated mainly for binary diagnoses such as
significant fibrosis. Recently, detailed fibrosis classifications for several non-invasive tests have been developed, but
their accuracy has not been thoroughly evaluated in comparison to liver biopsy, especially in clinical practice and
for Fibroscan. Therefore, the main aim of the present study was to evaluate the accuracy of detailed fibrosis
classifications available for non-invasive tests and liver biopsy. The secondary aim was to validate these accuracies
in independent populations.
Methods: Four HCV populations provided 2,068 patients with liver biopsy, four different pathologist skill-levels and
non-invasive tests. Results were expressed as percentages of correctly classified patients.
Results: In population #1 including 205 patients and comparing liver biopsy (reference: consensus reading by two
experts) and blood tests, Metavir fibrosis (FM) stage accuracy was 64.4% in local pathologists vs. 82.2% (p < 10
-3)i n
single expert pathologist. Significant discrepancy (≥ 2FM vs reference histological result) rates were: Fibrotest: 17.2%,
FibroMeter
2G: 5.6%, local pathologists: 4.9%, FibroMeter
3G: 0.5%, expert pathologist: 0% (p < 10
-3). In population #2
including 1,056 patients and comparing blood tests, the discrepancy scores, taking into account the error
magnitude, of detailed fibrosis classification were significantly different between FibroMeter
2G (0.30 ± 0.55) and
FibroMeter
3G (0.14 ± 0.37, p < 10
-3) or Fibrotest (0.84 ± 0.80, p < 10
-3). In population #3 (and #4) including 458
(359) patients and comparing blood tests and Fibroscan, accuracies of detailed fibrosis classification were,
respectively: Fibrotest: 42.5% (33.5%), Fibroscan: 64.9% (50.7%), FibroMeter
2G: 68.7% (68.2%), FibroMeter
3G: 77.1%
(83.4%), p < 10
-3 (p < 10
-3). Significant discrepancy (≥ 2F M) rates were, respectively: Fibrotest: 21.3% (22.2%),
Fibroscan: 12.9% (12.3%), FibroMeter
2G: 5.7% (6.0%), FibroMeter
3G: 0.9% (0.9%), p < 10
-3 (p < 10
-3).
Conclusions: The accuracy in detailed fibrosis classification of the best-performing blood test outperforms liver
biopsy read by a local pathologist, i.e., in clinical practice; however, the classification precision is apparently lesser.
This detailed classification accuracy is much lower than that of significant fibrosis with Fibroscan and even Fibrotest
but higher with FibroMeter
3G. FibroMeter classification accuracy was significantly higher than those of other non-
invasive tests. Finally, for hepatitis C evaluation in clinical practice, fibrosis degree can be evaluated using an
accurate blood test.
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Whatever the diagnostic means, liver fibrosis is usually
described in a synthetic, ordered manner, e.g., fibrosis
classification. The development of histological classifica-
tions, i.e., Metavir fibrosis (FM) [1] or Ishak [2] semi-
quantitative staging systems, was an initial step in this
field. These histological classifications permitted the
development of several non-invasive tests for the diag-
nosis of liver fibrosis, mainly due to hepatitis C virus
(HCV). For statistical reasons, these tests were con-
structed for binary diagnoses such as significant fibrosis
(i.e., bridging fibrosis) and included two classes of fibro-
sis stages (for example, FM0/1 vs. FM2/3/4). However,
these broad classifications are less precise than the origi-
nal histological classification. The prognostic interest of
detailed fibrosis classification has been demonstrated
[3]. Therefore, more detailed classifications reflecting
histological fibrosis stages were derived from fibrosis
test results.
Several types of fibrosis classifications are now avail-
able for non-invasive fibrosis tests, the most important
of which is detailed fibrosis class classification.W e
developed a fibrosis class classification method specific
to FibroMeter that defines six fibrosis classes based on
FM classification [4]. Fibrotest and Fibroscan are the
other tests with detailed fibrosis class classifications,b u t
methodology details are lacking [5,6]. Fibrosis class clas-
sification is used in the commercial versions of these
tests, especially Fibrotest and FibroMeter. Clinicians also
use a simplified classification for Fibroscan [7]. How-
ever, the diagnostic characteristics, especially accuracy,
of these classifications have not been thoroughly evalu-
ated or validated. We recently performed a preliminary
simple comparison in one population that suggested a
large difference between two blood tests [8].
These non-invasive tests are used in clinical practice. In
a previous study, we observed a poor agreement for liver
biopsy by local pathologist compared to expert patholo-
gist in clinical practice [9]. However, the accuracy of
pathologists for fibrosis classification has never been
compared with that of non-invasive tests in this setting.
T h e r e f o r e ,t h em a i na i mo ft h ep r e s e n ts t u d yw a st o
thoroughly evaluate the accuracies of the detailed fibro-
sis class classifications that have been developed for
non-invasive fibrosis tests in patients with chronic HCV
hepatitis based on liver biopsy as reference. The second-
ary aims were to compare these classification accuracies
to that of histological staging by liver biopsy measured
in clinical practice and to that of binary classification for
significant fibrosis, which is the usual accuracy assess-
ment of non-invasive tests. Finally, we evaluated the
robustness of these accuracies in independent HCV
populations.
Methods
Study design
We recruited different populations with liver biopsy to
evaluate the different diagnostic means. Thus, popula-
tion #1 provided different pathologist skill-levels and
blood tests. The large population #2 included only
blood tests. The more recent populations #3 and #4
included Fibroscan and blood tests. The four popula-
tions were separately analysed due to initial differences
in study designs; this allowed us to evaluate accuracy
robustness given these differences.
Populations
Patients with chronic HCV hepatitis, liver biopsy, blood
tests and available Fibroscan were consecutively
recruited in different populations: #1 to #4 described in
Table 1. Each population had different characteristics
and fibrosis assessments. Inclusion and exclusion cri-
teria are detailed in previous publications or below for
new populations. Briefly, patients did not receive anti-
viral or known anti-fibrotic treatments. Liver biopsy,
blood withdrawal and Fibroscan, when available, were
performed within a maximum interval of 6 months. The
study protocol conformed to the ethical guidelines of
the current Declaration of Helsinki and was approved
by local ethics committees. Patients gave written
consent.
Population #1 included 205 patients recruited from
primary, secondary or tertiary care centres as detailed
elsewhere [10] for a diagnostic study. Liver biopsy was
read initially by a local (first line) pathologist, then inde-
pendently by an expert from the Metavir group and
finally by two other experts with a consensus reading in
case of disagreement.
Population #2 included 1,056 patients provided by five
centres participating in the Sniff 17 study [11]. Thus,
individual patient data were available from five centres,
independent for study design, patient recruitment, and
blood marker determination. Blood and pathological
determinations were not centralized. Pathological assess-
ments were performed twice by the same pathologist in
Grenoble, once in Bordeaux and once each by two
pathologists in Angers, Tours and PACA region, with a
common final reading in cases of disagreement.
Population #3 included 458 patients provided by 19
centres participating in the Fibrostar study [12]. Blood
determination and liver interpretation were centralized.
Liver specimens were read by two senior experts, one of
whom was from the Metavir group.
Population #4 included 349 patients provided by three
centres participating in the Vindiag 7 study (exploratory
set) [13]. Blood and pathological (one senior expert in
each centre) determinations were not centralized.
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Fibrosis was staged in liver biopsy according to Metavir
staging [1] in all patients. This fibrosis stage classifica-
tion was used as the reference for the calculation of
accuracy. In population #1, where several readings were
available, the consensus reading by two experts was the
reference. “Expert pathologist” was defined as a senior
pathologist specialized in hepatology. At least one expert
pathologist was available in each study. Blood tests were
determined in all studies; we only evaluated here those
for which a detailed fibrosis class classification has been
described, i.e., FibroMeter [14] (Biolivescale, Angers,
France) and Fibrotest [5] (Biopredictive, Paris, France).
Second generation FibroMeter (FibroMeter
2G)[ 1 4 ] ,t h e
most widely studied, and a recent third generation Fib-
roMeter (FibroMeter
3G) [8] were evaluated. Two studies
also included Fibroscan (Echosens, Paris, France) as this
technique has only been available since 2004; usual
technical aspects have been described elsewhere [15].
All successful measurements of Fibroscan were included
in the calculations.
Fibrosis classifications
We distinguished as fibrosis degrees the histological
fibrosis stages and the fibrosis classes provided by non-
invasive tests and including one or several fibrosis stages.
Several fibrosis classifications were evaluated:
- The histological fibrosis stage classification into 5
FM stages (Figure 1a), as determined on a liver speci-
men by a pathologist. This was the reference for
accuracy.
- The binary diagnosis of significant fibrosis (2 classes,
Figure 1b) determined either on liver specimen or by
the diagnostic cut-off in non-invasive tests. This is
the usual diagnostic target of non-invasive tests and
thus served as a comparator for the detailed classifi-
cations. Indeed, as it was expected that a more
detailed classification would result in decreased
accuracy, this binary accuracy allowed for the eva-
luation of the putative accuracy loss.
- The fibrosis class classification used in non-invasive
tests, for which there are two main types:
￿ The classifications previously published for
blood tests and Fibroscan. There are 6 classes for
FibroMeter
2G (Figure 1c) [4], 7 for FibroMeter
3G
(Figure 1d), 8 for Fibrotest (Figure 1e) [5] and 6
for Fibroscan [6]. The methodology for the
development of FibroMeter
2G classification has
been published [4]: briefly, the percentiles of
blood test values were segmented into different
intervals according to an absolute majority prob-
ability (p ≥ 0.75) for one or several FM stages
(their number had to be ≤ 3). We developed an
improved fibrosis class classification for FibroMe-
ter
3G by using specific thresholds and changing
slightly the fibrosis classes (Figure 1d). The opti-
mization consisted in obtaining the best accu-
racy/precision ratio (number of Metavir fibrosis
stages per fibrosis class of the non-invasive test).
￿ The classifications derived from the cumulated
cut-offs calculated for different binary diagnostic
targets, usually significant fibrosis and cirrhosis.
Physicians normally use these kinds of classifica-
tions for the interpretation of Fibroscan results.
This process results in a classification including
3 classes: FM0/1, FM2/3, and FM4. The cut-off for
severe fibrosis (FM≥ 3) may also be used, result-
ing in a classification with 4 classes: FM0/1, FM2,
FM3, and FM4. We used the diagnostic cut-offs
calculated for HCV in the meta-analysis of Steb-
bing et al [7], giving the following three classes:
<8 . 4 4k P a :F M0/1, ≥ 8.44 kPa and < 16.14 kPa:
FM2/3, ≥ 16.14 kPa: FM4.
Statistics
Data were reported according to STARD statements
[16]. Quantitative variables were expressed as mean ±
SD, unless otherwise specified. Metavir fibrosis staging
w a su s e de i t h e ra sac a t e g o r i c a lv a r i a b l eo ra sas c o r e
(continuous variable) since we have shown a perfect lin-
ear correlation between Metavir fibrosis stages and frac-
tal dimension of fibrosis which reflects quantitative
architecture. For this reason, the results of fibrosis class
classification were also evaluated as a score, e.g., FM3/4
Table 1 Main characteristics of HCV populations
Population # Study name Patients
(n)
Liver biopsy length (mm) Blood tests FS Metavir F prevalence (%)
0 1234
1 Metavar 4 205 23 ± 7 x - 4.4 46.3 29.8 14.1 5.4
2 Sniff 17 1056 21 ± 8 x - 4.4 43.5 27.0 14.0 11.2
3 Fibrostar 458 25 ± 8 x x 6.7 45.1 17.9 15.6 14.8
4 Vindiag 7 349 25 ± 9 x x 1.4 30.7 35.5 20.6 11.7
x: test performed, FS: Fibroscan
Boursier et al. BMC Gastroenterology 2011, 11:132
http://www.biomedcentral.com/1471-230X/11/132
Page 3 of 13class was noted as 3.5. This score was only used in the
reflection evaluation of Metavir staging (see the fourth
figure). Multivariate analyses were based on binary logis-
tic regression. The performance of each test was mainly
expressed by the accuracy (i.e., true positives and nega-
tives or correct classification). The diagnostic cut-offs
used for significant fibrosis were determined by a pos-
teriori maximum Youden index (sensitivity + specificity
- 1). Discrepancy between diagnostic means can be eval-
uated as grade or score. The grade rate shows details,
especially the grade of significant discrepancy (≥ 2F M
stages). The discrepancy score took into account the
magnitude of the error. This score was defined as fol-
lows: 0 for correct classification, then 1, 2, 3 or 4 as per
the misclassification in FM stages between the liver spe-
cimen and the fibrosis class classification by the non-
invasive test. For example, a patient with histological
FM4 but classified as FM0/1 by blood test was scored 3.
The mean score permits a comparison between blood
tests. A low score means a low discrepancy magnitude.
Statistical software programs were SPSS version 17.0
(SPSS Inc., Chicago, IL, USA) and SAS 9.1 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
Liver biopsy
Population #1 was used to compare the accuracy of
pathologists with different expertise levels or vs. blood
tests. The prevalence of significant fibrosis was 49.3%.
Classification accuracy
Metavir expert as reference - The rates of correct classifi-
cation for significant fibrosis and FM stages by local
pathologists were, respectively: 77.1% and 52.2% (p < 10
-3
by McNemar test).
Consensus reading as reference - The rates of correct
classification of the two single (local or expert) patholo-
gists and two blood tests are listed in Table 2. Briefly,
detailed fibrosis classifications could be ordered according
to their accuracies as follows: FibroMeter
3G (89.0%) ≈
expert pathologist (82.2%) ≈ FibroMeter
2G (76.3%) > local
F3/4
F2/3/4
F2/3
F1/2/3
F1/2
F1
F0/1
F >= 2
F <= 1
F4
F3/4
F2/3
F1/2
F1
F0/1
Fibrosis class classification 
F4
F3
F2
F1/2 F1
F0/1
F0
F3/4 
4
3
2
1
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6  8 
FM 3G 
7 
1  0  1  0  1  0 
1  0 
F2 1 
F3 1 
F3 1 
F0/1 
FM 0 
FM 1 
FM 4 
FM 3 
FM 2 
FM 31  
FM 0/1 
FM 0/1 
FM 1 
FM 1/2 
FM 2/3 
FM 3/4 
FM 4  FM 3/4 
FM 3/4 
FM 0/1 
FM 0/1 
FM 1 
FM 1 
FM 1/2 
FM 1/2 
FM 2/3 
FM 2 
FM 3 
FM 31  
FM 21  
FM 4 
FM 0 
Liver b b biopsy b
A A A
Metavir fibrosis stages
5
0
F F F F 0 0
0 0
1
y
F F FM 1 1 1
4
F F F FM M M M 0 0 0
FM M M M 4 4 4 4
3
Li
F FM 3 3 3
2 FM M M M 2 2 2 2
B B B
Binary diagnosis of significant fibrosis
M2G
2
10 1  0 10
FM
2 F3 1 FM F F 3 3 3 1
G
F0/1 F F FM 0 F0 F0/ / /1 1 1
Fibrosis class classification
D E E E E
FM2G G 2G FT
6 8
FM M M 3G
7
1  0 1  0 1 0 1  0
F0/1 F F FM F0/ F0/0 1 1 / /1
F1 FM M M F F1 1 1 1
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Figure 1 Summary of different available fibrosis classifications in population #2. Metavir stages by liver biopsy (A), significant fibrosis by
FibroMeter
2G (FM) (B), fibrosis class classification by FibroMeter
2G (C) or FibroMeter
3G (D) or by Fibrotest (FT) (E). The central figure within the pie
chart indicates the number of fibrosis classes. Sectors correspond to patient proportions. The figures in the external circle of panels reflect the
values of blood test scores. FM denotes the Metavir fibrosis stages estimated by the classification.
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Page 4 of 13pathologists (64.4%) > Fibrotest (34.3%). FibroMeter
2G was
the only diagnostic method with no significant difference
in correct classification rates between significant fibrosis
diagnosis and fibrosis class classification.F i b r o M e t e r
3G
was the only diagnostic method with a significant increase
in correct classification rate of fibrosis class classification
compared to significant fibrosis diagnosis.
Discrepancy
The discrepancy scores were significantly different between
pathologists: local vs. expert: 0.55 ± 0.63, local vs. consen-
sus: 0.40 ± 0.58, expert vs. consensus: 0.17 ± 0.38 (p < 10
-3
by paired Friedman test). In addition, the proportions of
significant discrepancies (≥ 2F M stages) were significantly
different: local vs. expert: 7.3%, local vs. consensus: 4.9%,
expert vs. consensus: 0% (p < 10
-3 by paired Cochran test).
When considering consensus reading by experts as
reference, the discrepancy score of FibroMeter
2G was sig-
nificantly lower than that of local pathologists (p = 0.043)
but significantly higher than that of the expert patholo-
gist (p = 0.006, Table 3). This latter was not significantly
different from that of FibroMeter
3G (p = 0.077). The dis-
crepancy score of Fibrotest was significantly higher than
that of local or expert pathologists (p < 10
-3). In addition,
the proportions of significant discrepancies were very dif-
ferent: FibroMeter
3G < FibroMeter
2G < Fibrotest (p < 10
-
3 by paired Cochran test, Table 3).
Blood tests
Results are detailed in population #2 since it was the
largest (1,056 patients) for blood tests.
Table 2 Rates of correct classification (%, bold characters) as a function of diagnostic means in population #1
Significant fibrosis (FM ≥ 2) Fibrosis degree
a p
b
Local pathologists 85.9 64.4 <1 0
-3
Expert pathologist 91.4 82.2 <1 0
-3
Fibrotest (FT) 74.2 34.3 <1 0
-3
FibroMeter
2G (FM
2G) 75.3 76.3 0.860
FibroMeter
3G (FM
3G) 75.5 89.0 <1 0
-3
Comparison
b:p p -
All < 10
-3 <1 0
-3 -
Local pathologist vs. expert 0.184 < 10
-3 -
Local pathologist vs. FT 0.003 < 10
-3 -
Local pathologist vs. FM
2G 0.005 0.007 -
Local pathologist vs. FM
3G 0.004 < 10
-3 -
Expert pathologist vs. FT < 10
-3 <1 0
-3 -
Expert pathologist vs. FM
2G <1 0
-3 0.092 -
Expert pathologist vs. FM
3G <1 0
-3 0.126 -
FT vs. FM
2G 0.839 < 10
-3 -
FT vs. FM
3G 0.878 < 10
-3 -
FM
2G vs. FM
3G 1< 1 0
-3 -
The reference is consensus reading of liver biopsy.
a Metavir staging for pathologist or fibrosis class classification for blood tests
b By McNemar test (pair) or Friedman test (all)
Table 3 Discrepancy against a diagnostic reference.
Discrepancy score Significant discrepancies (%)
Population # 1
a 234 1
a 234
Local pathologist 0.40 ± 0.58 - - - 4.9 - - -
Expert pathologist 0.17 ± 0.38 - - - 0.0 - - -
Fibrotest 0.86 ± 0.77 0.84 ± 0.80 0.86 ± 0.93 0.92 ± 0.82 17.2 18.2 21.3 22.2
FibroMeter
2G 0.30 ± 0.58 0.30 ± 0.55 0.36 ± 0.62 0.38 ± 0.61 5.6 4.6 5.7 6.0
FibroMeter
3G 0.11 ± 0.33 0.14 ± 0.37 0.23 ± 0.44 0.17 ± 0.40 0.5 0.7 0.9 0.9
Fibroscan - - 0.50 ± 0.79 0.64 ± 0.74 - - 12.9 12.3
p
b <1 0
-3 <1 0
-3 <1 0
-3 <1 0
-3 <1 0
-3 <1 0
-3 <1 0
-3 <1 0
-3
Discrepancy score and significant discrepancies (≥ 2F M stages) with liver biopsy results as a function of fibrosis classifications by pathologists, blood tests or
Fibroscan according to the 4 populations.
a The reference is consensus reading of liver biopsy
b by paired Cochran or Friedman test
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The accuracy of fibrosis class classification by FibroMe-
ter
2G,F i b r o M e t e r
3G and Fibrotest have been presented
elsewhere [8] and will discussed further on.
Discrepancy
The discrepancy scores were significantly different
between FibroMeter
2G and FibroMeter
3G (p < 10
-3)o r
Fibrotest (p < 10
-3, Table 3). Details on discrepancy
grade are shown in Figure 2. In addition, the proportion
of significant discrepancies with FibroMeter
2G or Fibro-
Meter
3G was significantly lower than with Fibrotest (p <
10
-3 by McNemar test, Table 3).
Elastometry
Populations #3 and #4 were used to compare elastome-
try by Fibroscan and blood tests.
Classification accuracy
In population #3 (and #4), the accuracies of the fibro-
sis class classifications were 42.5% (33.5%) for Fibrot-
est, 64.9% (50.7%) for Fibroscan, 68.7% (68.2%) for
FibroMeter
2G, and 77.1% (83.4%) for FibroMeter
3G,p
<1 0
-3 (p < 10
-3) between non-invasive tests (Table 4).
Discrepancy
In population #3 and #4, the discrepancy scores were
significantly different: FibroMeter
3G <F i b r o M e t e r
2G <
Fibroscan < Fibrotest (p < 10
-3 by Friedman test in each
population, Table 3), with only FibroMeter
2G offering a
homogeneous score among FM stages (Figure 3). Details
on discrepancy grade a r es h o w ni nF i g u r e2 .T h ep r o -
portions of significant discrepancies were also signifi-
cantly different among fibrosis tests (p < 10
-3 by
Cochran test in each population, Table 3).
Reflection of histological stages by classifications
In population #2, the fibrosis class classification of
FibroMeter
2G (expressed as score) was more closely cor-
related with FM score than that of Fibrotest (Figure 4a/
b). By ANOVA, the mean FM score was significantly dif-
ferent as a function of fibrosis class classification of
FibroMeter
2G (F = 188, p < 10
-4) and Fibrotest (F = 83,
4
3
2
1
0
3
2
1
0
3  4 
4
3
2
1
0
3
2
1
0
FibroMeter2G  Fibrotest 
FibroMeter2G  Fibrotest  Fibroscan 
2
1
0
FibroMeter3G 
Population 2 
Population 3 
Figure 2 Rates of discrepancy grade of fibrosis class classifications by diagnostic tests in populations #2 (top) or #3 (bottom).T h e
figure indicates the difference in the number of fibrosis stage(s) between the blood test and liver biopsy. Thus, the grade 0 (green pie sector)
indicates agreement with liver biopsy.
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Page 6 of 13Table 4 Rates of correct classification by non-invasive means (%, bold characters) as a function of fibrosis
classification in populations #3 and #4.
Population #3 Population #4
Significant
fibrosis (FM ≥ 2)
Fibrosis class
classification
p
a Significant
fibrosis (FM ≥ 2)
Fibrosis class
classification
p
a
Fibrotest (FT) 71.3 42.5 <1 0
-3 75.2 33.5 <1 0
-3
FibroMeter
2G (FM
2G) 75.2 68.7 0.001 77.7 68.2 <1 0
-3
FibroMeter
3G (FM
3G) 74.0 77.1 0.255 76.8 83.4 0.011
Fibroscan (FS) 73.7 64.9 <1 0
-3 75.2 50.7 (52.8)
b <1 0
-3 (< 10
-3)
Comparison
a:p p - p p -
All 0.644 < 10
-3 -< 1 0
-3 <1 0
-3 -
FT vs. FM
2G 0.101 < 10
-3 - 0.314 < 10
-3 -
FT vs. FM
3G 0.064 < 10
-3 - 0.504 < 10
-3 -
FT vs. FS 0.344 < 10
-3 -1 < 1 0
-3 (< 10
-3)-
FM
2G vs. FM
3G 1< 1 0
-3 - 0.549 < 10
-3 -
FM
2G vs. FS 0.549 0.121 - 0.497 < 10
-3 (< 10
-3)-
FM
3G vs. FS 1 < 10
-3 - 0.699 < 10
-3 -
a By McNemar test (pair) or Friedman test (all)
b Classification into 6 [6] or 3 [7] classes in parentheses
Figure 3 Discrepancy between fibrosis class classifications by non-invasive tests and liver biopsy staging. Results (Y axis) are expressed as
a function of Metavir fibrosis (F) stage (X axis) in population #3. The left panel A indicates the mean score. The right panels show the details of
discrepancy grades for each diagnostic test: Fibrotest (B), Fibroscan (C), FibroMeter
2G (D) and FibroMeter
3G (E). The grade indicates the difference
in the number of fibrosis stage(s) between the blood test and liver biopsy. FT: Fibrotest, FS: Fibroscan, FM2: FibroMeter
2G, FM3: FibroMeter
3G.
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-4). However, the post hoc comparison (by
weighted Bonferroni test) showed highly significant dif-
ferences between each pair of fibrosis classes for Fibro-
Meter
2G, whereas this was not observed between several
pairs of contiguous classes of Fibrotest (Figure 4a/b).
Results in population #3 were similar to those
observed in population #2: significant discrimination
between most contiguous fibrosis classes by FibroMe-
ter
2G and any significant discrimination by Fibrotest
(Figure 4c/d). Fibroscan classification was poorly discri-
minating between contiguous classes (Figure 4e).
The fibrosis class classification might offer some
degree of imprecision in the classes including at least
two FM stages. Therefore, we evaluated the meaning of
test score within the largest class observed, i.e., FM1/2
class with FibroMeter
3G in population #2 (Figure 5). In
this class, FibroMeter
3G score was 0.32 ± 0.11 in FM1
vs. 0.37 ± 0.12 in FM2( p<1 0
-3).
Discussion
Liver biopsy
In this study, we have shown that the fibrosis class clas-
sification of an accurate blood test like FibroMeter
2G
provides better accuracy than Metavir staging by local
pathologists, which reflects clinical practice. Addition-
ally, its accuracy was not significantly different from that
of Metavir staging by a senior expert of the Metavir
group. Surprisingly, fibrosis class classification of Fibro-
Meter
3G provided a non-significantly higher accuracy
than that of the senior expert of the Metavir group.
Figure 4 Mean Metavir fibrosis score as a function of Metavir-based fibrosis class classifications. Results (± standard deviation, Y axis) are
expressed as a function of classifications (X axis) for: FibroMeter
2G (panels A and C, 6 classes), Fibrotest (panels B and D, 8 classes) or Fibroscan
(panel E, 6 classes) in populations #2 (top) or #3 (bottom). P by weighted Bonferroni test. The global relationship is indicated by Spearman’s
correlation coefficient (rs).
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ment of liver interpretation for fibrosis staging in clini-
cal practice [9].
These results nonetheless deserve some comments.
First, the accuracy of liver biopsy was significantly superior
to that of the best performing non-invasive test when the
diagnostic target was binary, such as significant fibrosis. In
other words, the development of detailed fibrosis class
classifications derived from FM stages compensated for the
lesser performance of non-invasive tests in binary diagnos-
tic targets, as observed in the literature and in the present
study. Second, fibrosis class classifications of non-invasive
tests seem less precise at first glance; we discuss this
important characteristic further on. Third, this study
underlines the issue of reference, as an expert from the
Metavir group underperformed the consensus reading
considered as reference in the present study. Thus, who,
or what, should be used as a reference? We have already
observed that a consensus reading improved reproducibil-
ity and thus could be considered as a reference [9]. How-
ever, we do not know if a panel reading would be a more
reliable reference. Liver biopsy does have innate limits,
such as sampling error and sample size effect, which sur-
pass those of liver interpretation. Indeed, two studies have
recently shown that blood tests for liver fibrosis were bet-
ter prognosis predictors than histological staging [17,18].
Non-invasive tests
Liver biopsy was used as the best standard [19]. Despite
its limits, it can be considered as a good reference for
the comparison between non-invasive tests since there
are no data to consider that the biopsy error was not
systematic (i.e., different between tests). In other words,
the accuracy of non-invasive tests is probably underesti-
mated but not their comparison. The results of the dif-
ferent populations are summarized in table 5. The
accuracies of fibrosis class classifications were different
among non-invasive tests in the present study in the fol-
lowing order: FibroMeter
3G >F i b r o M e t e r
2G >F i b r o s c a n
> Fibrotest. It should be underlined that these differ-
ences were observed in several independent populations.
In addition, from one study to another, the rank of
accuracy between tests was very reproducible. Thus, the
present results are robust. It should also be noted that
the authors of a recent study using a quite different
methodology in a small series (four patients) observed
an accuracy of less than 25% with the fibrosis stage clas-
sification of Fibrotest [20]. How thus can one explain
this apparent discrepancy between the close accuracies
of non-invasive tests for the usual binary diagnostic tar-
gets such as significant fibrosis, and the dissimilar
accuracies in their fibrosis class classifications?F i r s t ,a
single binary diagnostic target necessarily (mathemati-
cally) includes fewer sources of errors than a multiple-
stage classification. Second, the statistical methods used
to develop the fibrosis class classifications have to be
considered. We developed a new statistical method for
the development of a fibrosis class classification [4].
Thus, we obtained a fibrosis class classification with
FibroMeter
2G that included 6 classes, each one compris-
ing only one or two Metavir fibrosis stage(s). It should
be noted that the fibrosis class classifications of Fibrotest
or Fibroscan have been reported but the statistical
methodology used to establish them was not described
[5,6], nor their accuracy. The method used for three
stage classification of Fibroscan accumulates the mis-
classification rates of each diagnostic cut-off. We used
the cut-offs of Stebbing et al since their study was a
large recent meta-analysis restricted to HCV. The
method of fibrosis class classification that we developed
for FibroMeter
2G [4] was validated in the present study
by the reproducible accuracy measured in several inde-
pendent large populations. Thus, before using a non-
invasive test in clinical practice, it seems important to
verify the statistical methodology behind the construct
and its accuracy.
The present results indicate that the FibroMeter clas-
sification is robust, as its precision was expanded from 2
for significant fibrosis to 6 or 7 fibrosis classes at the
expense of only a 4% relative decrease in FibroMeter
2G
accuracy or a 12% relative increase in FibroMeter
3G
accuracy (87% in the largest series) [8]. It should be
noted that the accuracy/precision ratio was optimized
only for FibroMeter
3G [8] but this optimization could
F3/4
F2/3/4
F2/3
F1/2/3
F1/2
F1
F0/1
ϭϬ
&Dϭ͗Ϭ͘ϭϲ¢ ¢ ¢ ¢ Ϭ͘Ϭϭ
&Dϭ͗Ϭ͘ϯϮ¢ ¢ ¢ ¢ Ϭ͘ϭϭ
&DϮ͗Ϭ͘ϯϳ¢ ¢ ¢ ¢ Ϭ͘ϭϮ &DϮ͗Ϭ͘ϲϱ¢ ¢ ¢ ¢ Ϭ͘Ϭϰ
ƉфϭϬͲϯ
ƉфϭϬͲϯ
ƉфϭϬͲϯ
&D ϯͬϰ
&D Ϭͬϭ
&D ϭ
&D ϭͬϮ
&D Ϯͬϯ
&D ϯ±ϭ
&D Ϯ±ϭ
Figure 5 Meaning of blood test score (in grey rectangles) in
different Metavir fibrosis (FM) stages within the same class of
fibrosis class classification. Example of FM2 and FM1 stages in
FibroMeter
3G in population #2. Sectors correspond to patient
proportions. The figures on the top of the external circle reflect the
values (mean ± SD) of the blood test score for a single FM stage.
The significant difference between FM stages of contiguous classes
was mathematically expected contrary to that observed within a
single class.
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2G. This contrasts with
Fibrotest, which displayed a 49% relative decrease in
accuracy in the largest series between the binary diagno-
sis and its 8-class fibrosis classification [8]. In addition,
the FibroMeter
2G fibrosis class classification was more
discriminant than those of Fibrotest or Fibroscan in dis-
tinguishing fibrosis classes, especially two successive
classes (Figure 4). It has been suggested that the maxi-
mal theoretical accuracy may be around 90%, consider-
ing the limits of liver biopsy as a reference [21].
The discrepancy level between fibrosis class classifica-
tions of non-invasive tests and Metavir stages was
reflected by the discrepancy score and the proportion of
significant discrepancy (≥ 2F M), which markedly varied
among tests in the present study. FibroMeter
2G and
even FibroMeter
3G provided a significantly lower discre-
pancy score than Fibrotest or Fibroscan in all study
populations.
Best classifications for clinical use
The accuracy (correct classification in the whole popula-
tion) of binary diagnosis was superior or equal to that of
fibrosis class classification except for FibroMeter
3G.
However, the level of classification precision (less fibro-
sis stages per class) also has to be examined. When the
ratio between accuracy and precision is considered,
fibrosis class classification seems to provide the best per-
formance. Finally, the fibrosis class classification of
FibroMeter
2G had a significantly higher correct classifi-
cation (qualitative accuracy descriptor) and a signifi-
cantly lower discrepancy level (quantitative accuracy
descriptor better reflecting disagreement than the for-
mer) compared to local pathologists. In addition, Fibro-
Meter
3G compared favourably with expert pathologist
for those characteristics. This better accuracy for the
fibrosis class classification of FibroMeters as compared
to liver biopsy would seem to provide a strong argument
for their use in clinical practice despite their lesser pre-
cision. In other words, FibroMeters had fewer errors
than liver biopsy interpretation in clinical practice. Fig-
ure 6 also shows that a blood test has a robust diagnos-
tic reproducibility in clinical practice, compared to other
diagnostic means. However, this issue of precision can
be refined.
Interpreting classifications
Based on FM stages, fibrosis class classifications provide
multiple classes of FM stages according to blood test
values [4]. Thus, FibroMeter
2G fibrosis class classifica-
tion provided the following new classes: FM0/1, FM1,
FM1/2, FM2/3, FM3/4 and FM4. These correspond to the
following FibroMeter fibrosis stages expressed in single
Metavir score: FM0.5, FM1, FM1.5, FM2.5, FM3.5, and
FM4. They can furthermore be translated into the fol-
lowing new FibroMeter
2G fibrosis (FFM)s t a g e s :F FM0,
FFM1, FFM2, FFM3, FFM4a n dF FM5. This last classifica-
tion assumes that there is less error with non-invasive
tests than with liver biopsy, as suggested by several stu-
dies [22,23]. Therefore, the interest of these new classifi-
cations, based on “blood” fibrosis stages, has to be
tested independently of their native histological refer-
ence by using clinical events as an endpoint. This could
be accomplished through a prognostic study as pre-
viously done for blood tests used as scores [17,18] from
which classifications are derived. Finally, it should be
noted that within the largest FibroMeter
3G fibrosis class,
the score progression of blood test well reflected the
histological progression (Figure 5).
Limits
The prevalence of significant fibrosis in the four popula-
tions was close to that (48%) of a reference population
of 33,121 patients with HCV and liver biopsy [24]. The
studies including Fibroscan were not based on an
Table 5 Summary of correct classification rates (%) and score/grade discrepancy (2 bottom lines)
Liver biopsy FibroMeter Fibrotest Fibroscan
2G 3G
Population # 1 1 1 2 3 4 1 2 3 4 1 2 3 4 3 4
Pathologist Local
a Expert - - - - - - - - - - - - - -
Metavir FM staging 52.2/64.4 82.2 - - - - - - - - - - - - - -
Binary diagnosis
b 77.1/85.9 91.4 75.3 78.1* 75.2 77.7 75.5 77.9* 74.0 76.8 74.2 74.5* 71.3 75.2 73.7 75.2
Fibrosis class classification
c - - 76.3 74.9* 68.7 68.2 89.0 86.9* 77.1 83.4 34.3 37.9* 42.5 33.5 64.9 50.7
Discrepancy score
d 0.55/0.40 0.17 0.30 0.30 0.36 0.38 0.11 0.14 0.23 0.17 0.86 0.84 0.86 0.92 0.50 0.64
Significant discrepancy (%)
e 7.3/4.9 0.0 5.6 4.6 5.7 6.0 0.5 0.7 0.9 0.9 17.2 18.2 21.3 22.2 12.9 12.3
Results are presented according to different classifications and diagnostic means in the 4 populations with hepatitis C.
a The first figure refers to the expert as reference and the second to the consensus reading as reference
b for significant fibrosis; results indicated with * were provided by a previous study [8]
c by blood test; results indicated with * were provided by a previous study [8]
d Mean
e ≥ 2F M stage
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Page 10 of 13intention-to-diagnose analysis since unsuccessful mea-
surements were not included. This would decrease the
accuracy by about 5% as already shown in another study
[25] but not modify the hierarchy of tests regarding
a c c u r a c y .I ts h o u l db eu n d e r l i n e dt h a tl i v e rb i o p s yh a s
other indications than liver fibrosis.
Conclusions
Liver biopsy is useful for fibrosis staging if the reading
is performed by an expert, or even better, by consen-
sus including preferably at least one expert. Accuracies
varied very significantly between the fibrosis class clas-
sifications of the non-invasive tests. With the best per-
forming test, this classification has two advantages:
increased precision and accuracy compared to a binary
diagnosis of significant fibrosis; and similar or higher
accuracy when compared to histological staging per-
formed in clinical practice conditions. However, the
accuracy/precision ratio was higher with Metavir
staging by definition, since this was the reference.
These results, observed in hepatitis C, should be evalu-
ated in other causes (see Additional File 1). Finally, the
classification of a good-performing test permits the
evaluation of the degree of fibrosis in settings where
liver biopsy is not available or feasible, such as in epi-
demiological studies.
Additional material
Additional file 1: Supplementary results. We present a glossary of
fibrosis classifications in Additional File 1, Table S1. We also present here
detailed results on score and grade of discrepancy, the reflection of
histological stages by classifications and performance profiles of blood
tests as well as the accuracies of fibrosis class classifications in causes of
chronic liver disease other than HVC.
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Figure 6 Schematic reliability of diagnostic means. In clinical practice, a blood test is more reliable than liver pathology since the blood test
is based on an algorithm that was calculated with expert pathologist as reference (black arrow with red background). There is little procedure
variability for blood tests due to excellent interlaboratory reproducibility, contrary to the large inter-observer disagreement for liver pathology
and, to a lesser degree, for elastometry. The size of observers is proportional to published observer variability.
Boursier et al. BMC Gastroenterology 2011, 11:132
http://www.biomedcentral.com/1471-230X/11/132
Page 11 of 13Acknowledgements and funding
The authors thank other investigators from:
Metavar 4
C. Degott, V. Paradis (Clichy), S. Garcia (Marseille), MC. Saint-Paul (Nice), Ch.
Sattonet (Cagnes s/mer)
SNIFF 17 study
Angers: S. Michalak, A. Konaté, C. Ternisien, A. Chevailler, F. Lunel, M-C.
Rousselet, W. Mansour; PACA:
Ph. Halfon, M. Bourlière, D. Ouzan, A. Tran, D. Botta, Ch. Renou, Ch.
Sattonnet, M-C. Saint-Paul, Th. Benderitter, S. Garcia, H-P. Bonneau, G.
Penaranda; Tours: Y.Bacq, A. de Muret, M-C. Bréchot; Grenoble: V. Leroy, N.
Sturm, M-N. Hilleret, P. Faure, J-C. Renversez, F. Morel, C. Trocme; Bordeaux:
V. de Ledinghen, J. Foucher, L. Castera, P. Couzigou, P-H. Bernard, W.
Merrouche, P. Bioulac-Sage, B. Le Bail; and Clichy: C. Degott, V. Paradis.
Fibrostar study
Hepatologists: R. Poupon, A. Poujol, Saint-Antoine, Paris; A. Abergel,
Clermont-Ferrand; J.P. Bronowicki, Nancy; J.P. Vinel, S. Metivier, Toulouse; V. De
Ledinghen, Bordeaux; O. Goria, Rouen; M. Maynard-Muet, C. Trepo, Lyon; Ph.
Mathurin, Lille; D. Guyader, H. Danielou, Rennes; O. Rogeaux, Chambéry; S. Pol,
Ph. Sogni, Cochin, Paris; A. Tran, Nice; P. Calès, Angers; P. Marcellin, T. Asselah,
Clichy; M. Bourlière, V. Oulès, Saint Joseph, Marseille; D. Larrey, Montpellier; F.
Habersetzer, Strasbourg; M. Beaugrand, Bondy; V Leroy, MN Hilleret, Grenoble.
Biologists: R-C. Boisson, Lyon Sud; M-C. Gelineau, B. Poggi, Hôtel Dieu, Lyon;
J-C. Renversez, Candice Trocmé, Grenoble; J. Guéchot, R. Lasnier, M.
Vaubourdolle, Paris; H. Voitot, Beaujon, Paris; A. Vassault, Necker, Paris; A.
Rosenthal-Allieri, Nice; A. Lavoinne, F. Ziegler, Rouen; M. Bartoli, C. Lebrun,
Chambéry; A. Myara, Paris Saint-Joseph; F. Guerber, A. Pottier, Elibio, Vizille.
Pathologists: E-S. Zafrani, Créteil; N. Sturm, Grenoble.
Methodologists: A. Bechet, J-L Bosson, A. Paris, S. Royannais, CIC, Grenoble;
A. Plages, Grenoble.s
We also thank the following contributors: Gilles Hunault, Pascal Veillon,
Gwénaëlle Soulard; and Kevin L. Erwin (for English proofreading).
Grant Support
PHRC (clinical research funding program) of the French Department of
Health for SNIFF 17 in 1994 and 2002, ANRS (French national agency for
AIDS and Viral Hepatitis) for HC EP 23 Fibrostar.
Author details
1Liver-Gastroenterology department, University Hospital, Angers, France.
2HIFIH laboratory, UPRES 3859, IFR 132, University, PRES UNAM, Angers,
France.
3Laboratory of Biochemistry and Molecular Biology, University
Hospital, Angers, France.
4Department of Cell and Tissue Pathology,
University Hospital, Angers, France.
5Liver-Gastroenterology department,
University Hospital; INSERM/UJF U823, IAPC, IAB, University, Grenoble, France.
Authors’ contributions
JB: planning and conducting the study, collecting and interpreting data,
drafting the manuscript, read and approved the final manuscript. SB:
statistical analysis, read and approved the final manuscript. FO: collecting
and interpreting data, read and approved the final manuscript. YG: collecting
and interpreting data (biochemical analysis), read and approved the final
manuscript. IFH: collecting and interpreting data, read and approved the
final manuscript. MCR: collecting and interpreting data (pathological
analysis), read and approved the final manuscript. JPZ: planning and
conducting the Fibrostar study, collecting and interpreting data, read and
approved the final manuscript. PC: planning and conducting the study,
collecting and interpreting data, drafting the manuscript, read and approved
the final manuscript
Competing interests
Paul Calès, Isabelle Fouchard Hubert and Frédéric Oberti have stock
ownership in BioLiveScale Inc. BioLiveScale has a license for FibroMeter from
Angers University. Other authors: no conflicts of interest to declare.
Received: 2 January 2011 Accepted: 30 November 2011
Published: 30 November 2011
References
1. Intraobserver and interobserver variations in liver biopsy interpretation
in patients with chronic hepatitis C. The French METAVIR Cooperative
Study Group. Hepatology 1994, 20(1 Pt 1):15-20.
2. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H,
Desmet V, Korb G, MacSween RN, et al: Histological grading and staging
of chronic hepatitis. J Hepatol 1995, 22(6):696-699.
3. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE,
Ghany MG, Mills AS, Nash SR, Govindarajan S, et al: Prognostic value of
Ishak fibrosis stage: findings from the hepatitis C antiviral long-term
treatment against cirrhosis trial. Hepatology 2010, 51(2):585-594.
4. Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, de Muret A,
Sturm N, Hunault G, Penaranda G, et al: Diagnostic accuracy,
reproducibility and robustness of fibrosis blood tests in chronic hepatitis
C: a meta-analysis with individual data. Clin Biochem 2008, 41(16-
17):1368-1376.
5. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D,
Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic
value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure)
and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol
2004, 3(1):8.
6. de Ledinghen V, Vergniol J: Transient elastography (FibroScan).
Gastroenterol Clin Biol 2008, 32(6 Suppl 1):58-67.
7. Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR, Mandalia S, Bower M,
Gazzard B, Nelson M: A meta-analysis of transient elastography for the
detection of hepatic fibrosis. J Clin Gastroenterol 2010, 44(3):214-219.
8. Cales P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N,
Zarski JP, Rousselet MC: Optimization and robustness of blood tests for
liver fibrosis and cirrhosis. Clin Biochem 2010, 43(16-17):1315-1322.
9. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP,
Cales P: Sources of variability in histological scoring of chronic viral
hepatitis. Hepatology 2005, 41(2):257-264.
10. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A,
Botta D, Renou C, Brechot MC, et al: Comparison of test performance
profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol
2007, 46(3):395-402.
11. Cales P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J,
Bourliere M, de Muret A, Sturm N, et al: Evaluating the accuracy and
increasing the reliable diagnosis rate of blood tests for liver fibrosis in
chronic hepatitis C. Liver Int 2008, 28(10):1352-1362.
12. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC,
Bosson JL, Guyader D, Renversez JC, et al: Comparison of nine blood tests
and transient elastography for liver fibrosis in chronic hepatitis C: The
ANRS HCEP-23 study. J Hepatol 2011.
13. Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J,
Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y, et al: A new combination
of blood test and fibroscan for accurate non-invasive diagnosis of liver
fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011,
106(7):1255-1263.
14. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A,
Gallois Y, Ternisien C, Chevailler A, Lunel F: A novel panel of blood
markers to assess the degree of liver fibrosis. Hepatology 2005,
42(6):1373-1381.
15. Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le
Tallec V, Oberti F, Fouchard-Hubert I, Dib N, et al: The combination of a
blood test and Fibroscan improves the non-invasive diagnosis of liver
fibrosis. Liver Int 2009, 29(10):1507-1515.
16. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Moher D, Rennie D, de Vet HCW, Lijmer JG: The STARD statement for
reporting studies of diagnostic acuracy: explanation and elaboration.
Clin Chem 2003, 49(1):7-18.
17. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R,
Wheeler D, Contos M, West AB, et al: Prediction of clinical outcomes in
primary biliary cirrhosis by serum enhanced liver fibrosis assay.
Hepatology 2008, 48(5):1549-1557.
18. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N,
Dauvois B, Prevot S, Ngo Y, Munteanu M, et al: Diagnostic and prognostic
values of noninvasive biomarkers of fibrosis in patients with alcoholic
liver disease. Hepatology 2009, 49(1):97-105.
19. Bedossa P, Carrat F: Liver biopsy: the best, not the gold standard. J
Hepatol 2009, 50(1):1-3.
20. Gressner OA, Beer N, Jodlowski A, Gressner AM: Impact of quality control
accepted inter-laboratory variations on calculated Fibrotest/Actitest
scores for the non-invasive biochemical assessment of liver fibrosis. Clin
Chim Acta 2009, 409(1-2):90-95.
Boursier et al. BMC Gastroenterology 2011, 11:132
http://www.biomedcentral.com/1471-230X/11/132
Page 12 of 1321. Mehta SH, Lau B, Afdhal NH, Thomas DL: Exceeding the limits of liver
histology markers. J Hepatol 2009, 50(1):36-41.
22. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le
Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, et al: Prospective
analysis of discordant results between biochemical markers and biopsy
in patients with chronic hepatitis C. Clin Chem 2004, 50(8):1344-1355.
23. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I,
Allemand I, Bertrand JJ, Rosenthal-Allieri A, et al: Independent prospective
multicenter validation of biochemical markers (fibrotest-actitest) for the
prediction of liver fibrosis and activity in patients with chronic hepatitis
C: the fibropaca study. Am J Gastroenterol 2006, 101(3):547-555.
24. Thein HH, Yi Q, Dore GJ, Krahn MD: Estimation of stage-specific fibrosis
progression rates in chronic hepatitis C virus infection: a meta-analysis
and meta-regression. Hepatology 2008, 48(2):418-431.
25. Boursier J, Isselin G, Fouchard-Hubert I, Oberti F, Dib N, Lebigot J, Bertrais S,
Gallois Y, Cales P, Aube C: Acoustic radiation force impulse: a new
ultrasonographic technology for the widespread noninvasive diagnosis
of liver fibrosis. Eur J Gastroenterol Hepatol 2010, 22(9):1074-1084.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/11/132/prepub
doi:10.1186/1471-230X-11-132
Cite this article as: Boursier et al.: Comparison of accuracy of fibrosis
degree classifications by liver biopsy and non-invasive tests in chronic
hepatitis C. BMC Gastroenterology 2011 11:132.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Boursier et al. BMC Gastroenterology 2011, 11:132
http://www.biomedcentral.com/1471-230X/11/132
Page 13 of 13